Daniel E. Casey, David A. Sack, J. L. Peters, Herbert Y. Meltzer, Muriel Maurel-Raymondet, Carlos Morra, Sophie Frangou, Marie Agathe Zimmerman, Ravi Anand, Carlo Andrea Robotti, Vinod Kumar, Larry Alphs, Pedro L. Delgado, Eva Morik, K. Ranga Rama Krishnan, Vanda Benešová, Pierre Michel Llorca, Hannale Heila, Bernardo Carpiniello, Alberto Giannelli, Ann M. Mortimer, George T. Grossberg, Daniel L. Zimbroff, Shôn Lewis, Guy Chouinard, Saide Altinsan, Gyorgy Ostorharics-Horvath, Liliana Dell'Osso, Likiana Avigo, Jörg Pahl, Robert Kerwin, George M. Simpson, James C.-Y. Chou, Thomas Posever, Frederick Young, Robin Emsley, Elisabeth Bokowska, Oladapo Tomori, Santha Vaidain, Zdeòka Vyhnándová, Stephen Martin, Mary Ann Knesevich, Libor Chvila, Akos Kassaifarkas, Mojtaba Noursalehi, Vera Folnegovic, Richard Greenberg, Michael D. Lesem, Michael G. Plopper, Giovanni B. Cassano, Delbert Robinson, Nancy Temkin, Doris Gundersen, Ivo Paclt, Pedro Gargoloff, Frederic Khidichian, Laszlo Mod, Luis Bengochea, Naveed Iqbal, George Hsu, Steven G. Potkin, Thomas Fahy, Chuanchieh Hsu, Carl Eisdorfer, Rosario Pioli, Alan I. Green, Jack S. Krasuski, Miro Jakovljević, Siemion Altman, Mark Hyman Rapaport, Phillip Seibel, Jean Dalery, Richard C. Josiassen, Frédéric Rouillon, Veronica W. Larach, Isaac Sakinsofsky, Richard Balon, István Bitter, H. Edward Logue, and Ira D. Glick
Background Enhanced ability to reliably identify risk factors for suicidal behavior permits more focused decisions concerning treatment interventions and support services, with potential reduction in lives lost to suicide. Methods This study followed 980 patients at high risk for suicide in a multicenter prospective study for 2 years after randomization to clozapine or olanzapine. A priori predictors related to diagnosis, treatment resistance, and clinical constructs of disease symptoms were evaluated as possible predictors of subsequent suicide-related events. Results Ten baseline univariate predictors were identified. Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide. Predictive clinical features included greater baseline scores on the InterSePT scale for suicidal thinking, the Covi Anxiety Scale, the Calgary Depression Scale (CDS), and severity of Parkinsonism. Subsequent multivariate analysis revealed the number of hospitalizations in the previous 36 months, baseline CDS, severity of Parkinson’s, history of substance abuse, and lifetime suicide attempts. Clozapine, in general, was more effective than olanzapine in decreasing the risk of suicidality, regardless of risk factors present. Conclusions This is the first prospective analysis of predictors of suicide risk in a large schizophrenic and schizoaffective population judged to be at high risk for suicide. Assessment of these risk factors may aid clinicians in evaluating risk for suicidal behaviors so that appropriate interventions can be made.